|
Oct 9
|
Amarin Corp PLC (AMRN) Q2 2024 Earnings Call Highlights: Navigating Revenue Challenges and ...
|
|
Oct 1
|
Amarin Announces Two Upcoming Investor Events
|
|
Aug 22
|
Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress
|
|
Jul 23
|
Denali Therapeutics (DNLI) Stock Jumps 9.7%: Will It Continue to Soar?
|
|
Jun 4
|
Sector Update: Health Care Stocks Rise Tuesday Afternoon
|
|
Jun 4
|
Amarin Board of Directors Announces CEO Transition
|
|
May 28
|
Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A.
|
|
May 6
|
Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference
|
|
May 3
|
Amarin Corporation plc (NASDAQ:AMRN) Q1 2024 Earnings Call Transcript
|
|
May 3
|
Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year?
|
|
May 2
|
Amarin First Quarter 2024 Earnings: EPS Beats Expectations
|
|
May 1
|
Amarin's (AMRN) Q1 Earnings and Revenues Surpass Estimates
|
|
May 1
|
Amarin Plc (AMRN) Q1 2024 Earnings Call Transcript
|
|
May 1
|
Amarin Corp PLC (AMRN) Q1 2024 Earnings: Navigating Challenges with Strategic Focus
|
|
May 1
|
Amarin Reports First Quarter 2024 Business Update and Financial Results
|
|
Apr 24
|
Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event
|
|
Apr 22
|
Amarin Announces Results of Annual General Meeting of Shareholders
|
|
Apr 15
|
Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024
|
|
Apr 8
|
Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24
|
|
Apr 8
|
New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups
|